MultiCell appoints Stephen Chang new chief executive officer

By E. Janene Geiss

Philadelphia, May 26 - MultiCell Technologies, Inc. said Friday that Stephen M. Chang has been appointed as its new chief executive officer in addition to his current role as president.

W. Gerald Newmin, outgoing chief executive officer, will continue in his role as co-chairman and secretary of the company, according to a company news release.

Chang joined MultiCell as president Feb. 1, 2005, bringing extensive biopharmaceutical experience, notably in the development and management of strategic opportunities, the formation of corporate alliances and bringing therapeutic products to market.

Chang was formerly chief executive officer at privately held Astral Therapeutics, a San Diego biotechnology company whose novel therapies for diabetes and other autoimmune diseases were recently acquired by MultiCell.

Chang also is president of Cures, a coalition of patient advocates, biotechnology companies, pharmaceutical companies and venture capitalist dedicated to ensuring the safety and continued research and development of innovative life-saving medications.

Chang was chief science officer and vice president of Canji Inc./Schering Plough Research Institute in San Diego from 1998 to 2004, managing four large external biotech corporate partnerships with Transgene, Myriad Genetics, Genzyme and Immune Response.

Chang earned his doctoral degree in biological chemistry, molecular biology and biochemistry from the University of California, Irvine. He has filed more than 40 patents worldwide and has published extensively.

MultiCell is a San Diego biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.